Unlike simple generic versions, Phosphagenics’ TPM®/Daptomycin product (developed in collaboration with Agila Specialties and Mylan) has multiple technical advantages to commercially differentiate it from Cubicin® and other generic daptomycin competitors. We believe this differentiation supports the potential for significantly improved market share and revenue. This TPM®/Daptomycin product is at present in late stage development towards a 505(b)(2) regulatory filing in the USA.
Unlike simple generic versions, Phosphagenics’ TPM®/Daptomycin...
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add POH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.0¢ |
Change
0.000(0.00%) |
Mkt cap ! n/a | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| POH (ASX) Chart |
Day chart unavailable
